UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
Web page optimized for Internet Explorer
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
Services and products
For more information: contact: Prof. O. Feron (+32-2-764
5264 or e-mail to olivier.feron@uclouvain.be)
Services:
Oncology:
o
Biomarker
detection and validation from plasma and serum of cancer patients
o
Screening
of synthetic or natural compounds for anti-tumor and/or anti-angiogenic
activity
under
hypoxic and/or normoxic conditions
o
2D-DIGE
to identify differential expression of proteins, post-translational
modifications (PTM)
or
protein-protein interactions
Cardiovascular and oncology:
o
In vitro and in vivo evaluation of
cardiovascular or anticancer drugs on animal and human cell/tissues
Products:
Oncology:
o
Auto-antibodies
as prognostic, predictive or monitoring cancer biomarkers
o
Lead
compounds with (hypoxia-selective) anti-tumor and/or anti-angiogenic
activity
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
UCL-IREC-FATH5349, Tour
Vésale 5ème étage
Avenue E. Mounier 52,
B-1200 Brussels, Belgium
(Metro Station Alma)
|
|
|
|
|
|
|
Dr Jean-Luc Balligand
jl.balligand@uclouvain.be
+32-2-764 5262
Dr Chantal Dessy
chantal.dessy@uclouvain.be
+32-2-764 5263
Other team members (click here)
|
|
|
|
|
|
Secretariat :
Anne Huyghe
anne.huyghe@uclouvain.be
+32-2-764 5260
Fax: +32-2-764
5269
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
Prof.
Jean-Luc Balligand
Under construction
|
|
|
|
Prof. Chantal
Dessy
Under construction
|
|
|
|
|
Prof. Olivier Feron
WFARM1305
Eléments de Pathologie
WFARM2180
Organotoxicité et Cancer
WFARM2133
Pharmacologie Spéciale
(cardiovasculaire et cancer)
WFARM2211
Pharmacothérapie Intégrée
WFARM2515
Pharmacologie Moléculaire
WFARM2228
Intégration Finalité Spéc.
SBIO M208 (FUNDP)
Thérapies anti-cancéreuses
Total heures : 53 (vol.1) + 20
(vol.2)
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
Oncology
Dr. Olivier
FERON
|
|
|
|
|
Web
page optimized for Internet Explorer
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
Oncology
Dr. Pierre
Sonveaux
|
|
|
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
Cardiovascular
Dr. Jean-Luc Balligand
|
|
|
|
Curriculum
vitae
Publications
Theses
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
Cardiovascular
Dr. Chantal
Dessy
|
|
|
|
Curriculum
vitae
Publications
Theses
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
|
Oncology
Experimental & Preclinical Research
O. Feron
|
|
|
Different aspects of the tumor microenvironment
are studied, including hypoxia, the end-products of the metabolism and the
recruitment of host-derived cells. The major questions addressed are how
these different parameters and/or actors influence tumor angiogenesis,
metastatic progression and tumor response to conventional anti-cancer
therapies (ie, radio-, chemo- and immunotherapy).
Major current projects are:
1) Study of the role of intermittent vs. continuous hypoxia in tumors and in particular,
through transcriptomic and proteomic studies, their differential impact on
(i) the phenotype of tumor endothelial cells and the consecutive
resistance to anti-angiogenic treatments and (ii) the metastatic potential
of tumor cells and their resistance to apoptosis.
2) Study of the tumor metabolism end-products,
including (i) the role of lactate as a (recycled) energy fuel for
oxidative tumor cells and (ii) the reconversion of nitrite into NO
under tumor low pH and low pO2 conditions and the therapeutic
and pathogenic consequences.
3) Study of the role of hematopoietic and immune cells
(macrophages and lymphocytes) on the tumor progression, with a focus on
the vasculogenic pathways and the immunosuppressive mechanisms in tumors.
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
|
Oncology
Translational & Clinical Research
O. Feron
|
|
|
This research
is directly derived from the expertise acquired through basic research:
1) Study of
the serological and seric proteome
of tumor-bearing mice and cancer patients to identify circulating tumor
auto-antibodies or proteins as biomarkers of cancer progression and
response to treatments.
2)
Development of tumor
vascular-targeting nanoparticles to deliver therapeutic entities such
as radio-isotopes and siRNA to tumors.
3)
Implementation of a technological
platform to identify anti-angiogenic and anti-tumor compounds issued
from hypotheses-driven neosynthesis of chemicals or
ethnopharmacology-selected plant extracts.
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
|
|
|
Experimental
& Preclinical Research
Under construction
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
|
|
|
PROTEOMICS
MICROSCOPY
IN VIVO IMAGING &
MEASUREMENTS
The above technological platforms are
completed with conventional and high-standard molecular biology,
biochemistry and cell biology equipments. A variety of mouse models of
human tumor xenografts and metastases are also available.
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
|
|
|
o Ettan
IpgPhor III (GE) [1st dim-electroph]
o Ettan
DALT6 (GE) [2nd dim-electroph]
o TE77
transfer units GE)
o Ettan
DIGE Imager (GE)
o Decyder
analysis software (GE)
o
SE600 large gels electrophoresis unit (GE)
o SG100
gradient maker (GE)
o Ettan
Spot Picker (GE)
o
Home-made ELISA
kit development
o
Microplate reader & injectors (Victor 5, PE)
o Akta Microscale liquid chromatography
(GE)
o
Access to Mass
Spectrometry for protein identification
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
|
Oncology
In vivo
Imaging &
Measurements
O. Feron
|
|
|
o In
vivo bioluminescence detection (IVIS, Xenogen)
o Intravital
microscopy: fluorescence microscopes (Axioskop, Zeiss)
& camera EBCD
(Hammamatsu)
o Laser
Doppler imager (LDI, Moor)
o Telemetry (DSI) for hemodynamic measurements
o Microdialysis
analyzer (ISCUS)
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
|
|
|
o
Axio-Imager and Apotome pseudo-confocal microscopy (Zeiss)
+ AxioCam
o
Axiovert Fluorescence microscopy (Zeiss)
+ MRC5 camera (Zeiss)
o
Axio-observer (Z1, Zeiss) microscopy incl. O2
and CO2 modules
+ MRC camera for videomicroscopy (Zeiss)
|
|
UCL - Pole of Pharmacology and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
|
|
|
Cardio-
vascular
Team Members
|
|
|
|
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
|
|
|
o 2000-04 Agnès Brouet – Mandataire
Télévie.
o 2000-04 Pierre Sonveaux – Aspirant
FNRS.
o 2002-06 Réginald Ansiaux – Mandataire
Télévie (co-prom., prom. B. Gallez, UCL)
o 2002-07 Philippe Martinive –
Mandataire FRIA (co-prom. V. Grégoire, UCL).
o 2003-07 Julie De Wever – Mandataire
Télévie.
o 2003-08 Françoise Frérart –
Mandataire FRIA (co-prom. A. Noël, ULg).
o 2004-09 Géraldine Daneau – Aspirant
FNRS
o 2005-09 Florence Lair – Mandataire
Télévie
o 2006- Florence Defresne –
Aspirant FNRS
o 2009- Aude Lebreton –
Mandataire Télévie (co-prom. V. Préat, UCL)
o 2009- Marie Grandjean –
Mandataire FRIA
o 2009- Emmanuel Seront –
Mandataire Télévie (co-prom. JP. Machiels, UCL)
o 2009- Nihed Draoui- Mandataire
Télévie (co-prom. O. Riant, UCL)
o 2009- Christophe De Saedeleer –
Mandataire Télévie (co-prom., prom. P. Sonveaux)
o 2010 Samuel Branders –
Mandataire Télévie (co-porm. P. Dupont)
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
Dr. O. Feron
MS & BS
students
|
|
|
|
Master students (MS-SBIM) :
-
2003-04 : Carole Baaziz
-
2003-04 : Joëlle De Vries
-
2004-05 : Sébastien Colette
-
2007-09 : Caroline Huygens
Master students (MS-FARM-finalité approfondie – Etudiants-chercheurs)
:
-
2002-04 : Géraldine Daneau
-
2003-05 : Florence Defresne
-
2006-08 : Alexandra Smoos, Elise Quaghebeur
-
2007-09 : Christophe De Saedeler
-
2008-09 : Marie Grandjean
-
2008-10 : Valérie Sapin, Nathalie Gillard
-
2009-11 : Joséphine Samain
Master
students (MS-Medicine – Etudiants-chercheurs) :
-
2010- Julie Vandepapeliere
-
2010- Quentin Delmez
Master students (MS-FARM-finalité spécialisée) :
-
2008-09: Véronique Goncette, Pauline
Plaitin, Ludovic Thoumsin
-
2009-10 Deborah Manderlier, Amélie Nachtergaele, Zineb El Kharaj,
Amélie Skok,
Pierre
Sourdeau, Sofia Murad
-
2010-11 Grégory Leroy, Eilen Lenoble,
Stéphanie Magotteaux, Sarah Smets
Bachelor students
(BS) :
-
2000 : Fatima Benali
-
2001 : Olivier Mullens, Arnaud Delouvroy
-
2002 : Cédric Siperius, Sandra Strollo
-
2003 : Hélène Berger, Meltem Teke
-
2004 : Frédéric Mommens, Maxime Moisse
-
2005 : Marie Palumbo, Soundes Bourouis,
Emilie Baert, Caroline Huygens
-
2006 : Céline Guilbaud
-
2007 : Karlien
Pieters, Stéphane Van Cauwenberghe
-
2008 : Irène
Mailleux, Laurenne Petit
-
2009 : Sabrina
François, Philippe de Sany
-
2010 : Marie
Conte, Céline Evlard
|
|
UCL - Pole of Pharmacology
and Therapeutics
MD/IREC/FATH
|
|
|
|
|
|
|
|
|
|
|
-
Current Position :
o Professor, UCL, 2008-
o FNRS Research Director, 2009-
o Head, Angiogenesis and Cancer
Research Lab
-
Diploma and Training :
o MS Pharmaceutical Sciences, UCL,
1990
o MS Biomedical Sciences, UCL,
1992
o PhD in Molecular Pharmacology,
UCL, 1995
o Research Associate, Brigham and
Women’s Hospital, 1996-98
o Instructor in Medicine, Harvard Medical School,
1997
o Assistant Professor UCL and Chercheur
qualifié FNRS, 1999-2004
o Associate Professor UCL and Maître de
recherches FNRS, 2005-09
o Agrégé Ens. Sup., UCL, 2005
-
Awards and Honors :
o Member of the Royal Academy
of Medicine (2009)
o Laureate: Prix Galien (1999), Prix Orbita
(2000), Prix MSD-BLC (2000), Prix
de la Fondation Bekales (2001), AACR-Pezcoller Foundation Award (2004), Prix Eugène De Somer (2008),
Prix Lambertine-Lacroix (2010)
-
Publications :
o Author of >125 publications
and 10 book chapters
o h-Index (2010) = 37
-
Link to full CV
version
|
|
